AbbVie (ABBV) EBIT Margin Growth (3y) (2015 - 2026)
Peer Comparison
| # |
Company |
Market Cap |
Enterprise Value |
Gross Profit (Qtr) |
EBIT Margin Growth (3y) (Qtr) |
| 1 |
Novartis Ag |
107,124,802.25 Bn |
107,124,802.25 Bn |
- |
- |
| 2 |
Eli Lilly |
969.00 Bn |
963.72 Bn |
16.22 Bn |
2,500.00 |
| 3 |
Johnson & Johnson |
539.46 Bn |
517.41 Bn |
15.96 Bn |
-91.00 |
| 4 |
AbbVie |
376.92 Bn |
367.57 Bn |
10.78 Bn |
395.00 |
| 5 |
Merck |
285.00 Bn |
279.35 Bn |
12.09 Bn |
-4,555.00 |
| 6 |
Amgen |
177.58 Bn |
165.55 Bn |
5.87 Bn |
-53.00 |
| 7 |
Gilead Sciences |
163.22 Bn |
155.50 Bn |
5.52 Bn |
1,031.00 |
| 8 |
Pfizer |
145.86 Bn |
133.09 Bn |
-1.21 Bn |
-9,003.00 |
| 9 |
Bristol Myers Squibb |
111.90 Bn |
101.44 Bn |
8.07 Bn |
-338.00 |
| 10 |
Gsk |
88.34 Bn |
83.66 Bn |
- |
- |
| Date | Value |
| Mar 31, 2026 |
395.00 |
| Dec 31, 2025 |
-904.00 |
| Sep 30, 2025 |
-1,901.00 |
| Jun 30, 2025 |
914.00 |
| Mar 31, 2025 |
-687.00 |
| Dec 31, 2024 |
-4,395.00 |
| Sep 30, 2024 |
-353.00 |
| Jun 30, 2024 |
-417.00 |
| Mar 31, 2024 |
-881.00 |
| Dec 31, 2023 |
-474.00 |
| Sep 30, 2023 |
-885.00 |
| Jun 30, 2023 |
2,534.00 |
| Mar 31, 2023 |
-1,916.00 |
| Dec 31, 2022 |
-906.00 |
| Sep 30, 2022 |
21.00 |
| Jun 30, 2022 |
-1,859.00 |
| Mar 31, 2022 |
-361.00 |
| Dec 31, 2021 |
6,348.00 |
| Sep 30, 2021 |
-833.00 |
| Jun 30, 2021 |
-155.00 |
| Mar 31, 2021 |
-505.00 |
| Dec 31, 2020 |
406.00 |
| Sep 30, 2020 |
-1,328.00 |
| Jun 30, 2020 |
-3,112.00 |
| Mar 31, 2020 |
499.00 |
| Dec 31, 2019 |
1,140.00 |
| Sep 30, 2019 |
-584.00 |
| Jun 30, 2019 |
4,258.00 |
| Mar 31, 2019 |
22.00 |
| Dec 31, 2018 |
-6,241.00 |
| Sep 30, 2018 |
664.00 |
| Jun 30, 2018 |
-28,159.00 |
| Mar 31, 2018 |
312.00 |
| Dec 31, 2017 |
3,064.00 |
| Sep 30, 2017 |
1,939.00 |
| Jun 30, 2017 |
758.00 |
| Mar 31, 2017 |
721.00 |
| Dec 31, 2016 |
402.00 |
| Sep 30, 2016 |
727.00 |
| Jun 30, 2016 |
-3,236.00 |
| Mar 31, 2016 |
809.00 |
| Dec 31, 2015 |
-196.00 |
| Sep 30, 2015 |
-369.00 |
| Jun 30, 2015 |
28,330.00 |
| Mar 31, 2015 |
1,004.00 |